Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: KRSA), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cyclerion Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cyclerion Therapeutics's position in the market.
Korsana Biosciences (KRSA) closed its merger with Cyclerion Therapeutics and a $380 million private placement, with shares expected to begin trading on Nasdaq on September 9, 2026.
The combined company will operate as Korsana Biosciences and list on the Nasdaq Capital Market under ticker “KRSA,” with a new CUSIP of 23255M303. The $380 million financing, consisting of common stock and pre-funded warrants from a broad syndicate of institutional and strategic investors, together with existing cash, results in post-transaction cash and cash equivalents of approximately $475 million, which is expected to fund operations into 2029.
Under the merger terms, each Korsana share converts into approximately 0.2074 shares of the combined company, reflecting Cyclerion’s 1-for-7 reverse stock split completed immediately prior to closing. After the reverse split, private placement and merger, there are about 55.1 million common shares and common stock equivalents outstanding, excluding equity awards.
Lead program KRSA-028, a shuttled antibody targeting amyloid beta for Alzheimer’s disease using the THETA™ platform, is advancing toward the clinic, with Phase 1 healthy volunteer data expected in mid-2027 and interim proof-of-concept data on amyloid plaque clearance in Alzheimer’s patients anticipated by late 2027 or early 2028.